Amgen/Takeda VEGF Inhibitor Motesanib Faces Setback In NSCLC
This article was originally published in PharmAsia News
Executive Summary
Partners Amgen and Takeda have pinned near-term oncology growth prospects on motesanib, a vascular endothelial growth factor inhibitor for the treatment of non-small cell lung cancer. Now motesanib is facing a setback; Amgen announced Nov. 19 that the Phase III MONET-1 study has been temporarily suspended after a planned safety review showed earlier mortality rates in the treatment group